Product Name: FGFR1 (809-822)
Product Number: PE-01AUD99
Size: 200 µg      Price:42.00
1 mg      $US84.00
5 mg      198.00
Peptide Name: FGFR1 (809-822)

Product Use: Services as a blocking peptide for use with the FGFR1-3 rabbit polyclonal antibody (Cat. No.: AB-NK062-3) that is also available from Kinexus. The peptide sequence is located in the C-terminus.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: CRHPAQLANGGLKRR

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Free carboxyl

Peptide Molecular Mass Calculated: 1677 Da

Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: FGFR1 pan-specific antibody (Cat. No.: AB-NK062-3)

Scientific Background: FGFR1 (Flt2) is a protein-tyrosine kinase of the TK group and FGFR family. It is a fibroblast growth factor receptor, and is alternatively spliced generating multiple variants that are differentially expressed during embryogenesis and in the adult body. It is highly expressed and widely distributed in most tested human tissues. FGF receptors plays an important role in multiple biological processes, including mesoderm induction and patterning, cell growth and migration, organ formation and bone growth. FGFR1 is involved in cell proliferation, differentiation, migration, and embryonic development. FGFR1 is activated by basic-FGF, which induces dimerization and transautophosphorylation. Phosphorylation of Y653 and Y654 increases kinase activity. Phosphorylation of Y766 induces interaction of FGFR1 with PLCg1 and SHB, induces FRS2 phosphorylation, and activation of RAS and MAPK signalling, leading to cell proliferation. Phosphorylation of Y154 induces receptor internalization. It can phosphorylate GAB1, PLCG1, FRS2, and SHB. FGFR1 has been linked with the development of Pfeiffer Syndrome (PS), Kallmann Syndrome Type 2 (KAL2), Stem Cell Leukemia Lymphoma Syndrome (SCLL), breast carcinomas (ductal), lung bronchoalveolar carcinomas and lung large cell carcinomas.